Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Retroperitoneal Sarcomas (TORNADO)
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to
assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant
chemotherapy